nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—MTOR—obesity	0.554	1	CbGaD
Pimecrolimus—CYP3A4—Sibutramine—obesity	0.0462	0.27	CbGbCtD
Pimecrolimus—CYP3A4—Benzphetamine—obesity	0.035	0.204	CbGbCtD
Pimecrolimus—CYP3A4—Bupropion—obesity	0.0298	0.174	CbGbCtD
Pimecrolimus—CYP3A4—Orlistat—obesity	0.0243	0.142	CbGbCtD
Pimecrolimus—CYP3A4—Cimetidine—obesity	0.0219	0.127	CbGbCtD
Pimecrolimus—CYP3A4—Topiramate—obesity	0.0143	0.0834	CbGbCtD
Pimecrolimus—MTOR—hindbrain—obesity	0.00358	0.125	CbGeAlD
Pimecrolimus—MTOR—respiratory system—obesity	0.00219	0.0766	CbGeAlD
Pimecrolimus—FKBP1A—respiratory system—obesity	0.00197	0.0689	CbGeAlD
Pimecrolimus—MTOR—cardiovascular system—obesity	0.00168	0.0587	CbGeAlD
Pimecrolimus—Everolimus—MTOR—obesity	0.00167	0.336	CrCbGaD
Pimecrolimus—FKBP1A—adrenal cortex—obesity	0.00165	0.0578	CbGeAlD
Pimecrolimus—FKBP1A—cardiovascular system—obesity	0.00151	0.0528	CbGeAlD
Pimecrolimus—MTOR—pituitary gland—obesity	0.00148	0.0519	CbGeAlD
Pimecrolimus—MTOR—adipose tissue—obesity	0.00148	0.0517	CbGeAlD
Pimecrolimus—MTOR—digestive system—obesity	0.00139	0.0487	CbGeAlD
Pimecrolimus—FKBP1A—pituitary gland—obesity	0.00133	0.0467	CbGeAlD
Pimecrolimus—FKBP1A—adipose tissue—obesity	0.00133	0.0465	CbGeAlD
Pimecrolimus—MTOR—adrenal gland—obesity	0.00133	0.0464	CbGeAlD
Pimecrolimus—FKBP1A—digestive system—obesity	0.00125	0.0438	CbGeAlD
Pimecrolimus—FKBP1A—adrenal gland—obesity	0.00119	0.0417	CbGeAlD
Pimecrolimus—MTOR—endocrine gland—obesity	0.00115	0.0402	CbGeAlD
Pimecrolimus—Temsirolimus—MTOR—obesity	0.00113	0.227	CrCbGaD
Pimecrolimus—MTOR—liver—obesity	0.00104	0.0363	CbGeAlD
Pimecrolimus—FKBP1A—endocrine gland—obesity	0.00103	0.0362	CbGeAlD
Pimecrolimus—Sirolimus—MTOR—obesity	0.000992	0.2	CrCbGaD
Pimecrolimus—Tacrolimus—MTOR—obesity	0.000992	0.2	CrCbGaD
Pimecrolimus—FKBP1A—liver—obesity	0.000932	0.0326	CbGeAlD
Pimecrolimus—Urticaria—Methamphetamine—obesity	0.000581	0.00488	CcSEcCtD
Pimecrolimus—Urticaria—Benzphetamine—obesity	0.00056	0.0047	CcSEcCtD
Pimecrolimus—Erythema—Diethylpropion—obesity	0.00056	0.0047	CcSEcCtD
Pimecrolimus—Ear pain—Sibutramine—obesity	0.000554	0.00465	CcSEcCtD
Pimecrolimus—Wheezing—Bupropion—obesity	0.000551	0.00463	CcSEcCtD
Pimecrolimus—Influenza like illness—Bupropion—obesity	0.000551	0.00463	CcSEcCtD
Pimecrolimus—Constipation—Phendimetrazine—obesity	0.00055	0.00461	CcSEcCtD
Pimecrolimus—Hypersensitivity—Methamphetamine—obesity	0.000539	0.00452	CcSEcCtD
Pimecrolimus—Gastroenteritis—Sibutramine—obesity	0.000533	0.00448	CcSEcCtD
Pimecrolimus—Oedema—Phentermine—obesity	0.000525	0.00441	CcSEcCtD
Pimecrolimus—Hypersensitivity—Benzphetamine—obesity	0.00052	0.00436	CcSEcCtD
Pimecrolimus—Nasal congestion—Sibutramine—obesity	0.000519	0.00436	CcSEcCtD
Pimecrolimus—Abdominal pain—Phendimetrazine—obesity	0.000508	0.00426	CcSEcCtD
Pimecrolimus—Diarrhoea—Methamphetamine—obesity	0.0005	0.0042	CcSEcCtD
Pimecrolimus—Dyspnoea—Phenylpropanolamine—obesity	0.00049	0.00411	CcSEcCtD
Pimecrolimus—Ear pain—Bupropion—obesity	0.000483	0.00405	CcSEcCtD
Pimecrolimus—Diarrhoea—Benzphetamine—obesity	0.000483	0.00405	CcSEcCtD
Pimecrolimus—Constipation—Phenylpropanolamine—obesity	0.00047	0.00394	CcSEcCtD
Pimecrolimus—Gastroenteritis—Bupropion—obesity	0.000465	0.0039	CcSEcCtD
Pimecrolimus—Otitis media—Topiramate—obesity	0.000465	0.0039	CcSEcCtD
Pimecrolimus—Headache—Methamphetamine—obesity	0.000458	0.00384	CcSEcCtD
Pimecrolimus—Face oedema—Sibutramine—obesity	0.000456	0.00383	CcSEcCtD
Pimecrolimus—Arthralgia—Cimetidine—obesity	0.000454	0.00381	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Phentermine—obesity	0.000454	0.00381	CcSEcCtD
Pimecrolimus—Nasal congestion—Bupropion—obesity	0.000452	0.0038	CcSEcCtD
Pimecrolimus—Constipation—Phentermine—obesity	0.000449	0.00377	CcSEcCtD
Pimecrolimus—Rhinorrhoea—Topiramate—obesity	0.000447	0.00375	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Orlistat—obesity	0.000446	0.00374	CcSEcCtD
Pimecrolimus—Headache—Benzphetamine—obesity	0.000442	0.00371	CcSEcCtD
Pimecrolimus—Breast disorder—Orlistat—obesity	0.000441	0.0037	CcSEcCtD
Pimecrolimus—Diarrhoea—Phendimetrazine—obesity	0.00044	0.00369	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Bupropion—obesity	0.000437	0.00367	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Cimetidine—obesity	0.000435	0.00365	CcSEcCtD
Pimecrolimus—Acne—Topiramate—obesity	0.00043	0.00361	CcSEcCtD
Pimecrolimus—Influenza—Orlistat—obesity	0.000422	0.00354	CcSEcCtD
Pimecrolimus—Asthma—Orlistat—obesity	0.000422	0.00354	CcSEcCtD
Pimecrolimus—Nausea—Benzphetamine—obesity	0.000419	0.00352	CcSEcCtD
Pimecrolimus—Urticaria—Phentermine—obesity	0.000417	0.0035	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Diethylpropion—obesity	0.000416	0.00349	CcSEcCtD
Pimecrolimus—Abdominal pain—Phentermine—obesity	0.000415	0.00349	CcSEcCtD
Pimecrolimus—CYP3A4—digestive system—obesity	0.000409	0.0143	CbGeAlD
Pimecrolimus—Asthma—Sibutramine—obesity	0.000409	0.00343	CcSEcCtD
Pimecrolimus—Influenza—Sibutramine—obesity	0.000409	0.00343	CcSEcCtD
Pimecrolimus—Dyspnoea—Diethylpropion—obesity	0.000408	0.00342	CcSEcCtD
Pimecrolimus—Hypersensitivity—Phenylpropanolamine—obesity	0.000405	0.00339	CcSEcCtD
Pimecrolimus—Headache—Phendimetrazine—obesity	0.000403	0.00338	CcSEcCtD
Pimecrolimus—Skin discolouration—Topiramate—obesity	0.000401	0.00336	CcSEcCtD
Pimecrolimus—Viral infection—Topiramate—obesity	0.000401	0.00336	CcSEcCtD
Pimecrolimus—Face oedema—Bupropion—obesity	0.000398	0.00334	CcSEcCtD
Pimecrolimus—Dysmenorrhoea—Topiramate—obesity	0.000398	0.00334	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Cimetidine—obesity	0.000396	0.00333	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Diethylpropion—obesity	0.000395	0.00331	CcSEcCtD
Pimecrolimus—Bronchitis—Sibutramine—obesity	0.000393	0.0033	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Orlistat—obesity	0.000392	0.00329	CcSEcCtD
Pimecrolimus—Constipation—Diethylpropion—obesity	0.000391	0.00328	CcSEcCtD
Pimecrolimus—Nausea—Phendimetrazine—obesity	0.000382	0.0032	CcSEcCtD
Pimecrolimus—Infestation—Orlistat—obesity	0.000376	0.00316	CcSEcCtD
Pimecrolimus—Infestation NOS—Orlistat—obesity	0.000376	0.00316	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Bupropion—obesity	0.000376	0.00316	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Sibutramine—obesity	0.000373	0.00313	CcSEcCtD
Pimecrolimus—Breast disorder—Bupropion—obesity	0.000372	0.00313	CcSEcCtD
Pimecrolimus—Constipation—Cimetidine—obesity	0.000372	0.00312	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Bupropion—obesity	0.000369	0.00309	CcSEcCtD
Pimecrolimus—Pneumonia—Sibutramine—obesity	0.000366	0.00308	CcSEcCtD
Pimecrolimus—Urticaria—Diethylpropion—obesity	0.000363	0.00305	CcSEcCtD
Pimecrolimus—Diarrhoea—Phentermine—obesity	0.00036	0.00302	CcSEcCtD
Pimecrolimus—Asthma—Bupropion—obesity	0.000356	0.00299	CcSEcCtD
Pimecrolimus—Influenza—Bupropion—obesity	0.000356	0.00299	CcSEcCtD
Pimecrolimus—Conjunctivitis—Sibutramine—obesity	0.000354	0.00297	CcSEcCtD
Pimecrolimus—Sinusitis—Orlistat—obesity	0.000353	0.00296	CcSEcCtD
Pimecrolimus—Influenza like illness—Topiramate—obesity	0.000351	0.00295	CcSEcCtD
Pimecrolimus—Vomiting—Phenylpropanolamine—obesity	0.000349	0.00293	CcSEcCtD
Pimecrolimus—Rash—Phenylpropanolamine—obesity	0.000346	0.00291	CcSEcCtD
Pimecrolimus—Dermatitis—Phenylpropanolamine—obesity	0.000346	0.0029	CcSEcCtD
Pimecrolimus—Body temperature increased—Cimetidine—obesity	0.000344	0.00289	CcSEcCtD
Pimecrolimus—Epistaxis—Sibutramine—obesity	0.000344	0.00288	CcSEcCtD
Pimecrolimus—Bronchitis—Bupropion—obesity	0.000343	0.00288	CcSEcCtD
Pimecrolimus—Sinusitis—Sibutramine—obesity	0.000342	0.00287	CcSEcCtD
Pimecrolimus—CYP3A4—endocrine gland—obesity	0.000338	0.0118	CbGeAlD
Pimecrolimus—Pharyngitis—Orlistat—obesity	0.000335	0.00281	CcSEcCtD
Pimecrolimus—Vomiting—Phentermine—obesity	0.000334	0.0028	CcSEcCtD
Pimecrolimus—Rash—Phentermine—obesity	0.000331	0.00278	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Bupropion—obesity	0.000331	0.00278	CcSEcCtD
Pimecrolimus—Dermatitis—Phentermine—obesity	0.000331	0.00278	CcSEcCtD
Pimecrolimus—Headache—Phentermine—obesity	0.000329	0.00276	CcSEcCtD
Pimecrolimus—Rhinitis—Sibutramine—obesity	0.000328	0.00275	CcSEcCtD
Pimecrolimus—Nausea—Phenylpropanolamine—obesity	0.000326	0.00274	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Bupropion—obesity	0.000325	0.00273	CcSEcCtD
Pimecrolimus—Pharyngitis—Sibutramine—obesity	0.000325	0.00272	CcSEcCtD
Pimecrolimus—Hypersensitivity—Cimetidine—obesity	0.00032	0.00269	CcSEcCtD
Pimecrolimus—Pneumonia—Bupropion—obesity	0.000319	0.00268	CcSEcCtD
Pimecrolimus—Infestation NOS—Bupropion—obesity	0.000318	0.00267	CcSEcCtD
Pimecrolimus—Infestation—Bupropion—obesity	0.000318	0.00267	CcSEcCtD
Pimecrolimus—Diarrhoea—Diethylpropion—obesity	0.000313	0.00262	CcSEcCtD
Pimecrolimus—Nausea—Phentermine—obesity	0.000312	0.00262	CcSEcCtD
Pimecrolimus—Conjunctivitis—Bupropion—obesity	0.000309	0.00259	CcSEcCtD
Pimecrolimus—Ear pain—Topiramate—obesity	0.000308	0.00258	CcSEcCtD
Pimecrolimus—Eye disorder—Sibutramine—obesity	0.000306	0.00257	CcSEcCtD
Pimecrolimus—Immune system disorder—Orlistat—obesity	0.000305	0.00256	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Orlistat—obesity	0.000305	0.00256	CcSEcCtD
Pimecrolimus—CYP3A4—liver—obesity	0.000305	0.0107	CbGeAlD
Pimecrolimus—Epistaxis—Bupropion—obesity	0.0003	0.00251	CcSEcCtD
Pimecrolimus—Sinusitis—Bupropion—obesity	0.000298	0.0025	CcSEcCtD
Pimecrolimus—Diarrhoea—Cimetidine—obesity	0.000298	0.0025	CcSEcCtD
Pimecrolimus—Gastroenteritis—Topiramate—obesity	0.000296	0.00249	CcSEcCtD
Pimecrolimus—Immune system disorder—Sibutramine—obesity	0.000295	0.00248	CcSEcCtD
Pimecrolimus—Malnutrition—Orlistat—obesity	0.000294	0.00247	CcSEcCtD
Pimecrolimus—Vomiting—Diethylpropion—obesity	0.000291	0.00244	CcSEcCtD
Pimecrolimus—Nasal congestion—Topiramate—obesity	0.000288	0.00242	CcSEcCtD
Pimecrolimus—Rash—Diethylpropion—obesity	0.000288	0.00242	CcSEcCtD
Pimecrolimus—Dermatitis—Diethylpropion—obesity	0.000288	0.00242	CcSEcCtD
Pimecrolimus—Headache—Diethylpropion—obesity	0.000286	0.0024	CcSEcCtD
Pimecrolimus—Rhinitis—Bupropion—obesity	0.000286	0.0024	CcSEcCtD
Pimecrolimus—Malnutrition—Sibutramine—obesity	0.000285	0.00239	CcSEcCtD
Pimecrolimus—Back pain—Orlistat—obesity	0.000285	0.00239	CcSEcCtD
Pimecrolimus—Pharyngitis—Bupropion—obesity	0.000283	0.00237	CcSEcCtD
Pimecrolimus—Vomiting—Cimetidine—obesity	0.000277	0.00232	CcSEcCtD
Pimecrolimus—Back pain—Sibutramine—obesity	0.000275	0.00231	CcSEcCtD
Pimecrolimus—Rash—Cimetidine—obesity	0.000274	0.0023	CcSEcCtD
Pimecrolimus—Dermatitis—Cimetidine—obesity	0.000274	0.0023	CcSEcCtD
Pimecrolimus—Headache—Cimetidine—obesity	0.000272	0.00229	CcSEcCtD
Pimecrolimus—Nausea—Diethylpropion—obesity	0.000272	0.00228	CcSEcCtD
Pimecrolimus—Angioedema—Orlistat—obesity	0.000269	0.00226	CcSEcCtD
Pimecrolimus—Eye disorder—Bupropion—obesity	0.000266	0.00224	CcSEcCtD
Pimecrolimus—Flushing—Bupropion—obesity	0.000265	0.00222	CcSEcCtD
Pimecrolimus—Angioedema—Sibutramine—obesity	0.00026	0.00218	CcSEcCtD
Pimecrolimus—Nausea—Cimetidine—obesity	0.000258	0.00217	CcSEcCtD
Pimecrolimus—Immune system disorder—Bupropion—obesity	0.000258	0.00216	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Bupropion—obesity	0.000257	0.00216	CcSEcCtD
Pimecrolimus—Cough—Orlistat—obesity	0.000257	0.00215	CcSEcCtD
Pimecrolimus—Face oedema—Topiramate—obesity	0.000254	0.00213	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000249	0.00209	CcSEcCtD
Pimecrolimus—Cough—Sibutramine—obesity	0.000248	0.00209	CcSEcCtD
Pimecrolimus—Malnutrition—Bupropion—obesity	0.000248	0.00208	CcSEcCtD
Pimecrolimus—Arthralgia—Sibutramine—obesity	0.000242	0.00203	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Orlistat—obesity	0.00024	0.00202	CcSEcCtD
Pimecrolimus—Oedema—Orlistat—obesity	0.00024	0.00202	CcSEcCtD
Pimecrolimus—Back pain—Bupropion—obesity	0.00024	0.00201	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Topiramate—obesity	0.00024	0.00201	CcSEcCtD
Pimecrolimus—Infection—Orlistat—obesity	0.000239	0.002	CcSEcCtD
Pimecrolimus—Breast disorder—Topiramate—obesity	0.000237	0.00199	CcSEcCtD
Pimecrolimus—Nervous system disorder—Orlistat—obesity	0.000235	0.00198	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Topiramate—obesity	0.000235	0.00197	CcSEcCtD
Pimecrolimus—Skin disorder—Orlistat—obesity	0.000233	0.00196	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Sibutramine—obesity	0.000232	0.00195	CcSEcCtD
Pimecrolimus—Oedema—Sibutramine—obesity	0.000232	0.00195	CcSEcCtD
Pimecrolimus—Infection—Sibutramine—obesity	0.000231	0.00194	CcSEcCtD
Pimecrolimus—Asthma—Topiramate—obesity	0.000227	0.0019	CcSEcCtD
Pimecrolimus—Angioedema—Bupropion—obesity	0.000227	0.0019	CcSEcCtD
Pimecrolimus—Skin disorder—Sibutramine—obesity	0.000226	0.00189	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Orlistat—obesity	0.000219	0.00184	CcSEcCtD
Pimecrolimus—Bronchitis—Topiramate—obesity	0.000218	0.00183	CcSEcCtD
Pimecrolimus—Cough—Bupropion—obesity	0.000217	0.00182	CcSEcCtD
Pimecrolimus—Paraesthesia—Orlistat—obesity	0.000216	0.00181	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Sibutramine—obesity	0.000212	0.00178	CcSEcCtD
Pimecrolimus—Arthralgia—Bupropion—obesity	0.000211	0.00177	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Topiramate—obesity	0.000211	0.00177	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.00021	0.00176	CcSEcCtD
Pimecrolimus—Paraesthesia—Sibutramine—obesity	0.000209	0.00175	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Orlistat—obesity	0.000207	0.00174	CcSEcCtD
Pimecrolimus—Dyspnoea—Sibutramine—obesity	0.000207	0.00174	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Topiramate—obesity	0.000207	0.00174	CcSEcCtD
Pimecrolimus—Pain—Orlistat—obesity	0.000205	0.00172	CcSEcCtD
Pimecrolimus—Pneumonia—Topiramate—obesity	0.000204	0.00171	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Bupropion—obesity	0.000203	0.0017	CcSEcCtD
Pimecrolimus—Oedema—Bupropion—obesity	0.000203	0.0017	CcSEcCtD
Pimecrolimus—Infestation NOS—Topiramate—obesity	0.000202	0.0017	CcSEcCtD
Pimecrolimus—Infestation—Topiramate—obesity	0.000202	0.0017	CcSEcCtD
Pimecrolimus—Infection—Bupropion—obesity	0.000201	0.00169	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Sibutramine—obesity	0.000201	0.00168	CcSEcCtD
Pimecrolimus—Pain—Sibutramine—obesity	0.000199	0.00167	CcSEcCtD
Pimecrolimus—Constipation—Sibutramine—obesity	0.000199	0.00167	CcSEcCtD
Pimecrolimus—Nervous system disorder—Bupropion—obesity	0.000199	0.00167	CcSEcCtD
Pimecrolimus—Skin disorder—Bupropion—obesity	0.000197	0.00165	CcSEcCtD
Pimecrolimus—Conjunctivitis—Topiramate—obesity	0.000197	0.00165	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Orlistat—obesity	0.000196	0.00165	CcSEcCtD
Pimecrolimus—Epistaxis—Topiramate—obesity	0.000191	0.0016	CcSEcCtD
Pimecrolimus—Urticaria—Orlistat—obesity	0.000191	0.0016	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Sibutramine—obesity	0.00019	0.00159	CcSEcCtD
Pimecrolimus—Sinusitis—Topiramate—obesity	0.00019	0.00159	CcSEcCtD
Pimecrolimus—Abdominal pain—Orlistat—obesity	0.00019	0.00159	CcSEcCtD
Pimecrolimus—Body temperature increased—Orlistat—obesity	0.00019	0.00159	CcSEcCtD
Pimecrolimus—Urticaria—Sibutramine—obesity	0.000185	0.00155	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Bupropion—obesity	0.000185	0.00155	CcSEcCtD
Pimecrolimus—Abdominal pain—Sibutramine—obesity	0.000184	0.00154	CcSEcCtD
Pimecrolimus—Body temperature increased—Sibutramine—obesity	0.000184	0.00154	CcSEcCtD
Pimecrolimus—Rhinitis—Topiramate—obesity	0.000182	0.00153	CcSEcCtD
Pimecrolimus—Paraesthesia—Bupropion—obesity	0.000182	0.00153	CcSEcCtD
Pimecrolimus—Dyspnoea—Bupropion—obesity	0.000181	0.00152	CcSEcCtD
Pimecrolimus—Pharyngitis—Topiramate—obesity	0.00018	0.00151	CcSEcCtD
Pimecrolimus—Tacrolimus—ALB—obesity	0.000179	0.036	CrCbGaD
Pimecrolimus—Hypersensitivity—Orlistat—obesity	0.000177	0.00148	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Bupropion—obesity	0.000175	0.00147	CcSEcCtD
Pimecrolimus—Pain—Bupropion—obesity	0.000173	0.00145	CcSEcCtD
Pimecrolimus—Constipation—Bupropion—obesity	0.000173	0.00145	CcSEcCtD
Pimecrolimus—Hypersensitivity—Sibutramine—obesity	0.000171	0.00144	CcSEcCtD
Pimecrolimus—Pruritus—Orlistat—obesity	0.00017	0.00143	CcSEcCtD
Pimecrolimus—Eye disorder—Topiramate—obesity	0.00017	0.00142	CcSEcCtD
Pimecrolimus—Flushing—Topiramate—obesity	0.000169	0.00141	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Bupropion—obesity	0.000166	0.00139	CcSEcCtD
Pimecrolimus—Pruritus—Sibutramine—obesity	0.000164	0.00138	CcSEcCtD
Pimecrolimus—Diarrhoea—Orlistat—obesity	0.000164	0.00138	CcSEcCtD
Pimecrolimus—Immune system disorder—Topiramate—obesity	0.000164	0.00138	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Topiramate—obesity	0.000164	0.00137	CcSEcCtD
Pimecrolimus—Urticaria—Bupropion—obesity	0.000161	0.00135	CcSEcCtD
Pimecrolimus—Body temperature increased—Bupropion—obesity	0.00016	0.00134	CcSEcCtD
Pimecrolimus—Abdominal pain—Bupropion—obesity	0.00016	0.00134	CcSEcCtD
Pimecrolimus—Diarrhoea—Sibutramine—obesity	0.000159	0.00133	CcSEcCtD
Pimecrolimus—Malnutrition—Topiramate—obesity	0.000158	0.00133	CcSEcCtD
Pimecrolimus—Erythema—Topiramate—obesity	0.000158	0.00133	CcSEcCtD
Pimecrolimus—Back pain—Topiramate—obesity	0.000153	0.00128	CcSEcCtD
Pimecrolimus—Vomiting—Orlistat—obesity	0.000153	0.00128	CcSEcCtD
Pimecrolimus—Rash—Orlistat—obesity	0.000151	0.00127	CcSEcCtD
Pimecrolimus—Dermatitis—Orlistat—obesity	0.000151	0.00127	CcSEcCtD
Pimecrolimus—Headache—Orlistat—obesity	0.00015	0.00126	CcSEcCtD
Pimecrolimus—Hypersensitivity—Bupropion—obesity	0.000149	0.00125	CcSEcCtD
Pimecrolimus—Vomiting—Sibutramine—obesity	0.000148	0.00124	CcSEcCtD
Pimecrolimus—Rash—Sibutramine—obesity	0.000147	0.00123	CcSEcCtD
Pimecrolimus—Dermatitis—Sibutramine—obesity	0.000146	0.00123	CcSEcCtD
Pimecrolimus—Headache—Sibutramine—obesity	0.000146	0.00122	CcSEcCtD
Pimecrolimus—Pruritus—Bupropion—obesity	0.000143	0.0012	CcSEcCtD
Pimecrolimus—Nausea—Orlistat—obesity	0.000143	0.0012	CcSEcCtD
Pimecrolimus—Diarrhoea—Bupropion—obesity	0.000139	0.00116	CcSEcCtD
Pimecrolimus—Nausea—Sibutramine—obesity	0.000138	0.00116	CcSEcCtD
Pimecrolimus—Cough—Topiramate—obesity	0.000138	0.00116	CcSEcCtD
Pimecrolimus—Arthralgia—Topiramate—obesity	0.000135	0.00113	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	0.000134	0.00112	CcSEcCtD
Pimecrolimus—Oedema—Topiramate—obesity	0.000129	0.00108	CcSEcCtD
Pimecrolimus—Vomiting—Bupropion—obesity	0.000129	0.00108	CcSEcCtD
Pimecrolimus—Infection—Topiramate—obesity	0.000128	0.00108	CcSEcCtD
Pimecrolimus—Rash—Bupropion—obesity	0.000128	0.00107	CcSEcCtD
Pimecrolimus—Dermatitis—Bupropion—obesity	0.000128	0.00107	CcSEcCtD
Pimecrolimus—Headache—Bupropion—obesity	0.000127	0.00107	CcSEcCtD
Pimecrolimus—Nervous system disorder—Topiramate—obesity	0.000127	0.00106	CcSEcCtD
Pimecrolimus—Skin disorder—Topiramate—obesity	0.000125	0.00105	CcSEcCtD
Pimecrolimus—Nausea—Bupropion—obesity	0.00012	0.00101	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Topiramate—obesity	0.000118	0.000987	CcSEcCtD
Pimecrolimus—Paraesthesia—Topiramate—obesity	0.000116	0.000973	CcSEcCtD
Pimecrolimus—Dyspnoea—Topiramate—obesity	0.000115	0.000966	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Topiramate—obesity	0.000111	0.000935	CcSEcCtD
Pimecrolimus—Pain—Topiramate—obesity	0.00011	0.000926	CcSEcCtD
Pimecrolimus—Constipation—Topiramate—obesity	0.00011	0.000926	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Topiramate—obesity	0.000106	0.000886	CcSEcCtD
Pimecrolimus—Urticaria—Topiramate—obesity	0.000103	0.00086	CcSEcCtD
Pimecrolimus—Abdominal pain—Topiramate—obesity	0.000102	0.000856	CcSEcCtD
Pimecrolimus—Body temperature increased—Topiramate—obesity	0.000102	0.000856	CcSEcCtD
Pimecrolimus—Hypersensitivity—Topiramate—obesity	9.51e-05	0.000798	CcSEcCtD
Pimecrolimus—Pruritus—Topiramate—obesity	9.13e-05	0.000766	CcSEcCtD
Pimecrolimus—Diarrhoea—Topiramate—obesity	8.83e-05	0.000741	CcSEcCtD
Pimecrolimus—Vomiting—Topiramate—obesity	8.21e-05	0.000689	CcSEcCtD
Pimecrolimus—Rash—Topiramate—obesity	8.14e-05	0.000683	CcSEcCtD
Pimecrolimus—Dermatitis—Topiramate—obesity	8.13e-05	0.000682	CcSEcCtD
Pimecrolimus—Headache—Topiramate—obesity	8.09e-05	0.000679	CcSEcCtD
Pimecrolimus—Nausea—Topiramate—obesity	7.67e-05	0.000643	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—BAD—obesity	1.34e-05	0.000109	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—DRD4—obesity	1.33e-05	0.000109	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CG—obesity	1.29e-05	0.000106	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT1—obesity	1.29e-05	0.000106	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SUCLG2—obesity	1.29e-05	0.000105	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ME1—obesity	1.29e-05	0.000105	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALDH6A1—obesity	1.29e-05	0.000105	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—POMC—obesity	1.28e-05	0.000105	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IRS1—obesity	1.28e-05	0.000105	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CRP—obesity	1.27e-05	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IRS2—obesity	1.27e-05	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CNR1—obesity	1.27e-05	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PRKCD—obesity	1.27e-05	0.000103	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MAPK8—obesity	1.25e-05	0.000102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TCF7L2—obesity	1.25e-05	0.000102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—DRD2—obesity	1.24e-05	0.000101	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MTHFR—obesity	1.24e-05	0.000101	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—POMC—obesity	1.23e-05	0.000101	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GCG—obesity	1.23e-05	0.0001	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTPN1—obesity	1.23e-05	0.0001	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—INS—obesity	1.22e-05	0.0001	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR4—obesity	1.22e-05	9.99e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—COX7C—obesity	1.21e-05	9.91e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—UCP1—obesity	1.21e-05	9.91e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PNPLA3—obesity	1.21e-05	9.91e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL2—obesity	1.2e-05	9.85e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IGF1—obesity	1.18e-05	9.69e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT2—obesity	1.18e-05	9.68e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IRS2—obesity	1.18e-05	9.62e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PRKCB—obesity	1.18e-05	9.62e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ICAM1—obesity	1.17e-05	9.58e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PRL—obesity	1.17e-05	9.56e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BAD—obesity	1.16e-05	9.5e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STK11—obesity	1.15e-05	9.42e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOE—obesity	1.15e-05	9.42e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—DGAT2—obesity	1.15e-05	9.39e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CS—obesity	1.15e-05	9.39e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SUCLA2—obesity	1.15e-05	9.39e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CPS1—obesity	1.15e-05	9.39e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CAV1—obesity	1.14e-05	9.33e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PLG—obesity	1.14e-05	9.32e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOA1—obesity	1.14e-05	9.31e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CD—obesity	1.14e-05	9.3e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SERPINE1—obesity	1.12e-05	9.2e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IRS1—obesity	1.11e-05	9.1e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FOXO3—obesity	1.11e-05	9.1e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADRB2—obesity	1.11e-05	9.07e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MUT—obesity	1.1e-05	8.96e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LIPE—obesity	1.1e-05	8.96e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TYK2—obesity	1.09e-05	8.95e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—STAT3—obesity	1.09e-05	8.95e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SOCS1—obesity	1.09e-05	8.93e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RHOA—obesity	1.09e-05	8.87e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SOCS3—obesity	1.08e-05	8.83e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3R1—obesity	1.07e-05	8.78e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOS3—obesity	1.07e-05	8.78e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—BAD—obesity	1.07e-05	8.77e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GNB3—obesity	1.06e-05	8.64e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYB5A—obesity	1.05e-05	8.59e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—DGAT1—obesity	1.05e-05	8.59e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF2—obesity	1.04e-05	8.49e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT2—obesity	1.03e-05	8.42e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GNAS—obesity	1.03e-05	8.41e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IRS1—obesity	1.03e-05	8.4e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MYC—obesity	1.02e-05	8.31e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TGFB1—obesity	1.01e-05	8.29e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ACLY—obesity	1.01e-05	8.27e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOB—obesity	1.01e-05	8.24e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CB—obesity	9.91e-06	8.11e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MTOR—obesity	9.91e-06	8.11e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CD—obesity	9.89e-06	8.09e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL5—obesity	9.84e-06	8.04e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—INS—obesity	9.84e-06	8.04e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALOX12—obesity	9.77e-06	7.99e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ENPP1—obesity	9.77e-06	7.99e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LPL—obesity	9.62e-06	7.87e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FOXO1—obesity	9.55e-06	7.81e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RPS6KB1—obesity	9.53e-06	7.8e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TYK2—obesity	9.52e-06	7.78e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT2—obesity	9.51e-06	7.77e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HMGCS1—obesity	9.46e-06	7.74e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3R1—obesity	9.34e-06	7.64e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ACADM—obesity	9.18e-06	7.51e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PFKFB3—obesity	9.18e-06	7.51e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PLIN1—obesity	9.18e-06	7.51e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SAT1—obesity	9.18e-06	7.51e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ANGPTL4—obesity	9.18e-06	7.51e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PNPLA2—obesity	9.18e-06	7.51e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CD—obesity	9.13e-06	7.47e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SERPINE1—obesity	9.03e-06	7.39e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CA—obesity	9.03e-06	7.38e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BCL2—obesity	8.99e-06	7.36e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYTB—obesity	8.93e-06	7.31e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—OXCT1—obesity	8.93e-06	7.31e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ACACB—obesity	8.93e-06	7.31e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNG—obesity	8.91e-06	7.29e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PRKCD—obesity	8.86e-06	7.25e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TYK2—obesity	8.79e-06	7.19e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RHOA—obesity	8.72e-06	7.13e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PNLIP—obesity	8.71e-06	7.12e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SRD5A1—obesity	8.71e-06	7.12e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HTR2A—obesity	8.67e-06	7.09e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CA—obesity	8.67e-06	7.09e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—C3—obesity	8.66e-06	7.08e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CA—obesity	8.63e-06	7.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3R1—obesity	8.63e-06	7.05e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS3—obesity	8.63e-06	7.05e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CB—obesity	8.62e-06	7.05e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—obesity	8.62e-06	7.05e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SDC3—obesity	8.5e-06	6.95e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAPK8—obesity	8.38e-06	6.85e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—STS—obesity	8.3e-06	6.79e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HK2—obesity	8.3e-06	6.79e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP26B1—obesity	8.3e-06	6.79e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IRS2—obesity	8.24e-06	6.74e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AGT—obesity	8.23e-06	6.73e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARD—obesity	8.13e-06	6.65e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LEP—obesity	8.06e-06	6.59e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOE—obesity	8.06e-06	6.59e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—obesity	7.99e-06	6.54e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CAV1—obesity	7.99e-06	6.53e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOA1—obesity	7.97e-06	6.52e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CB—obesity	7.96e-06	6.51e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC27A1—obesity	7.96e-06	6.51e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1B—obesity	7.95e-06	6.5e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—obesity	7.89e-06	6.45e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GLUL—obesity	7.81e-06	6.39e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—FABP4—obesity	7.81e-06	6.39e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ESR1—obesity	7.7e-06	6.29e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT3—obesity	7.66e-06	6.27e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—obesity	7.64e-06	6.25e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PRKCB—obesity	7.6e-06	6.22e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—F2—obesity	7.6e-06	6.22e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—BAD—obesity	7.51e-06	6.14e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—UCP2—obesity	7.4e-06	6.05e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—UCP3—obesity	7.4e-06	6.05e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HSD11B1—obesity	7.4e-06	6.05e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ECHS1—obesity	7.4e-06	6.05e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—obesity	7.37e-06	6.03e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAPK8—obesity	7.29e-06	5.96e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ADH1B—obesity	7.28e-06	5.96e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CG—obesity	7.28e-06	5.95e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IRS1—obesity	7.19e-06	5.88e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ACSL1—obesity	7.17e-06	5.86e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPAM—obesity	7.17e-06	5.86e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARGC1B—obesity	7.17e-06	5.86e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MYC—obesity	7.12e-06	5.82e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TGFB1—obesity	7.1e-06	5.81e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—obesity	7.08e-06	5.79e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—obesity	7.05e-06	5.77e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PCK1—obesity	6.96e-06	5.69e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—FADS1—obesity	6.96e-06	5.69e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HADH—obesity	6.96e-06	5.69e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—POMC—obesity	6.93e-06	5.66e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—INS—obesity	6.89e-06	5.63e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL2—obesity	6.78e-06	5.54e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ACP5—obesity	6.77e-06	5.54e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STAT3—obesity	6.66e-06	5.45e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1—obesity	6.66e-06	5.45e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT2—obesity	6.66e-06	5.44e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—G6PD—obesity	6.6e-06	5.4e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HK1—obesity	6.52e-06	5.33e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SREBF2—obesity	6.52e-06	5.33e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CD—obesity	6.4e-06	5.23e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SERPINE1—obesity	6.33e-06	5.17e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LPA—obesity	6.29e-06	5.15e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LPIN1—obesity	6.16e-06	5.04e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TYK2—obesity	6.15e-06	5.03e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—STAT3—obesity	6.15e-06	5.03e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RHOA—obesity	6.1e-06	4.99e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CA—obesity	6.04e-06	4.94e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOS3—obesity	6.04e-06	4.94e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3R1—obesity	6.04e-06	4.94e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOA5—obesity	6.03e-06	4.93e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CLOCK—obesity	5.76e-06	4.71e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC22A1—obesity	5.76e-06	4.71e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MYC—obesity	5.72e-06	4.68e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TGFB1—obesity	5.7e-06	4.66e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SULT2A1—obesity	5.61e-06	4.59e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GLP1R—obesity	5.61e-06	4.59e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CB—obesity	5.58e-06	4.56e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—DPYD—obesity	5.52e-06	4.51e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—obesity	5.35e-06	4.38e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PRKAR2B—obesity	5.31e-06	4.34e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—DCN—obesity	5.27e-06	4.31e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CA—obesity	5.26e-06	4.3e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CPT1A—obesity	5.13e-06	4.2e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NAMPT—obesity	5.03e-06	4.11e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LIPC—obesity	5e-06	4.09e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GCK—obesity	5e-06	4.09e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOC3—obesity	4.97e-06	4.06e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—obesity	4.94e-06	4.04e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CA—obesity	4.85e-06	3.97e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—obesity	4.85e-06	3.96e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CETP—obesity	4.82e-06	3.94e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SDC1—obesity	4.77e-06	3.9e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAPK8—obesity	4.71e-06	3.85e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKR1C3—obesity	4.69e-06	3.84e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—obesity	4.66e-06	3.81e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SCARB1—obesity	4.62e-06	3.78e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SREBF1—obesity	4.48e-06	3.67e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GOT2—obesity	4.36e-06	3.57e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STAT3—obesity	4.31e-06	3.52e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—obesity	4.3e-06	3.51e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—obesity	4.29e-06	3.51e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—FASN—obesity	4.27e-06	3.49e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—BCHE—obesity	4.25e-06	3.48e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2E1—obesity	4.1e-06	3.35e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NQO1—obesity	4.06e-06	3.32e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MYC—obesity	4e-06	3.27e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TGFB1—obesity	3.99e-06	3.27e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—obesity	3.96e-06	3.24e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GCG—obesity	3.89e-06	3.18e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC2A4—obesity	3.89e-06	3.18e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYCS—obesity	3.84e-06	3.14e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GGT1—obesity	3.77e-06	3.08e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GOT1—obesity	3.77e-06	3.08e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NCOA1—obesity	3.71e-06	3.03e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—STK11—obesity	3.66e-06	2.99e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP19A1—obesity	3.66e-06	2.99e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CA—obesity	3.4e-06	2.78e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—COMT—obesity	3.4e-06	2.78e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARGC1A—obesity	3.35e-06	2.74e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GNB3—obesity	3.35e-06	2.74e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HMOX1—obesity	3.34e-06	2.73e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GNAS—obesity	3.26e-06	2.67e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOB—obesity	3.2e-06	2.61e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LPL—obesity	3.05e-06	2.5e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—obesity	3.01e-06	2.46e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPX1—obesity	2.98e-06	2.43e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CD36—obesity	2.9e-06	2.37e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—obesity	2.78e-06	2.27e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTHFR—obesity	2.75e-06	2.25e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARA—obesity	2.7e-06	2.2e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AGT—obesity	2.61e-06	2.13e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOE—obesity	2.56e-06	2.09e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CAV1—obesity	2.53e-06	2.07e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOA1—obesity	2.53e-06	2.07e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CG—obesity	2.31e-06	1.89e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARG—obesity	2.23e-06	1.82e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—POMC—obesity	2.2e-06	1.8e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—INS—obesity	2.18e-06	1.79e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CD—obesity	2.03e-06	1.66e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALB—obesity	2e-06	1.64e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NOS3—obesity	1.92e-06	1.57e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3R1—obesity	1.92e-06	1.57e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CB—obesity	1.77e-06	1.45e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—obesity	1.75e-06	1.43e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CA—obesity	1.08e-06	8.82e-06	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—obesity	8.81e-07	7.2e-06	CbGpPWpGaD
